肝细胞癌：通过肝白血病因子向索拉非尼耐药演变 - Suppr

Suppr

超能文献

Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor.

作者信息

Musso Orlando, Beraza Naiara

机构信息

INSERM, Univ Rennes, INRA, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Rennes, France.

Gut Microbes and Health Research Programme, Quadram Institute, Norwich, UK.

出版信息

Gut. 2019 Oct;68(10):1728-1730. doi: 10.1136/gutjnl-2019-318999. Epub 2019 Jul 3.

DOI:10.1136/gutjnl-2019-318999

PMID:31270163

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6839724/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af29/6839724/b35a99efebf5/gutjnl-2019-318999f01.jpg

相似文献

Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor.

Gut. 2019 Oct;68(10):1728-1730. doi: 10.1136/gutjnl-2019-318999. Epub 2019 Jul 3.

Moving beyond sorafenib alone in advanced hepatocellular carcinoma: is hepatic arterial infusion chemotherapy the best option?

Ann Oncol. 2017 Mar 1;28(3):667. doi: 10.1093/annonc/mdw664.

Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms.

EBioMedicine. 2020 Feb;52:102644. doi: 10.1016/j.ebiom.2020.102644. Epub 2020 Jan 31.

Reply to: "Predictors of sorafenib benefit in patients with hepatocellular carcinoma".

J Hepatol. 2018 Mar;68(3):620-621. doi: 10.1016/j.jhep.2017.10.013. Epub 2017 Oct 24.

Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.

Clin Cancer Res. 2016 May 15;22(10):2555-64. doi: 10.1158/1078-0432.CCR-15-0499. Epub 2015 Nov 24.

Is Sorafenib an Optimal Treatment for Hepatocellular Carcinoma With Macrovascular Invasion or Metastatic Disease?

Hepatology. 2018 Aug;68(2):786. doi: 10.1002/hep.29862.

Long-term treatment of hepatocellular carcinoma with sorafenib.

Infez Med. 2013 Jun;21(2):167-8.

Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?

Gut. 2013 Dec;62(12):1674-5. doi: 10.1136/gutjnl-2013-304564. Epub 2013 Mar 12.

Sorafenib induced hepatic encephalopathy.

Acta Gastroenterol Belg. 2017 Oct-Dec;80(4):537-538.

Management of hepatocellular carcinoma recurrence after liver transplant is far from perfect.

Am J Surg. 2018 Aug;216(2):389-390. doi: 10.1016/j.amjsurg.2017.04.004. Epub 2017 Apr 25.

引用本文的文献

HLF and PPARα axis regulates metabolic-associated fatty liver disease through extracellular vesicles derived from the intestinal microbiota.

Imeta. 2025 Apr 7;4(2):e70022. doi: 10.1002/imt2.70022. eCollection 2025 Apr.

Identification of a Four-Gene Signature Associated with the Prognosis Prediction of Lung Adenocarcinoma Based on Integrated Bioinformatics Analysis.

Genes (Basel). 2022 Jan 27;13(2):238. doi: 10.3390/genes13020238.

The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma.

Front Cell Dev Biol. 2020 Feb 7;8:55. doi: 10.3389/fcell.2020.00055. eCollection 2020.

本文引用的文献

Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance.

Gut. 2019 Oct;68(10):1858-1871. doi: 10.1136/gutjnl-2018-317440. Epub 2019 May 22.

Retrodifferentiation of Human Tumor Hepatocytes to Stem Cells Leads to Metabolic Reprogramming and Chemoresistance.

Cancer Res. 2019 Apr 15;79(8):1869-1883. doi: 10.1158/0008-5472.CAN-18-2110. Epub 2019 Mar 5.

Is adaptive therapy natural?

PLoS Biol. 2018 Oct 2;16(10):e2007066. doi: 10.1371/journal.pbio.2007066. eCollection 2018 Oct.

Hepatocellular carcinoma.

Lancet. 2018 Mar 31;391(10127):1301-1314. doi: 10.1016/S0140-6736(18)30010-2. Epub 2018 Jan 5.

Hepatic Leukemia Factor Maintains Quiescence of Hematopoietic Stem Cells and Protects the Stem Cell Pool during Regeneration.

Cell Rep. 2017 Dec 19;21(12):3514-3523. doi: 10.1016/j.celrep.2017.11.084.

The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis.

Gut. 2018 Sep;67(9):1704-1715. doi: 10.1136/gutjnl-2016-313392. Epub 2017 Jul 28.

Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.

Sci Rep. 2016 Mar 11;6:22976. doi: 10.1038/srep22976.

Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.

Nat Genet. 2015 Sep;47(9):1020-1029. doi: 10.1038/ng.3362. Epub 2015 Jul 27.

Oncofetal signaling as a target for cancer therapy.

Semin Cancer Biol. 2014 Dec;29:1-2. doi: 10.1016/j.semcancer.2014.08.001. Epub 2014 Aug 8.

Evolution of the cancer stem cell model.

Cell Stem Cell. 2014 Mar 6;14(3):275-91. doi: 10.1016/j.stem.2014.02.006.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验